Agilent Technologies Files Definitive Additional Materials

TL;DR

AGILENT (AGLT) filed proxy materials - check for shareholder updates.

AI Summary

Agilent Technologies, Inc. filed a Definitive Additional Materials filing (DEFA14A) on February 21, 2025. This filing is related to their proxy statement and provides additional information for shareholders. The company is headquartered in Santa Clara, California, and operates in the laboratory analytical instruments sector.

Why It Matters

This filing provides shareholders with updated or supplementary information relevant to upcoming shareholder decisions or meetings, ensuring transparency and informed participation.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement update and does not indicate any immediate financial distress or significant operational changes.

Key Players & Entities

• AGILENT TECHNOLOGIES, INC. (company) — Registrant
• 0000950170-25-024558 (filing_id) — Accession Number
• 20250221 (date) — Filing Date
• Santa Clara, CA (location) — Company Headquarters

FAQ

From the Filing

0000950170-25-024558.txt : 20250221 0000950170-25-024558.hdr.sgml : 20250221 20250221090004 ACCESSION NUMBER: 0000950170-25-024558 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250221 DATE AS OF CHANGE: 20250221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AGILENT TECHNOLOGIES, INC. CENTRAL INDEX KEY: 0001090872 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 770518772 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-15405 FILM NUMBER: 25648585 BUSINESS ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: (408) 345-8886 MAIL ADDRESS: STREET 1: 5301 STEVENS CREEK BLVD, MS 1A-LC STREET 2: P.O. BOX 58059 CITY: SANTA CLARA STATE: CA ZIP: 95052-8059 FORMER COMPANY: FORMER CONFORMED NAME: AGILENT TECHNOLOGIES INC DATE OF NAME CHANGE: 19990816 FORMER COMPANY: FORMER CONFORMED NAME: HP MEASUREMENT INC DATE OF NAME CHANGE: 19990716 DEFA14A 1 a_-_defa14a_2025.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:       ☐ Preliminary Proxy Statement     ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))     ☐ Definitive Proxy Statement     ☒ Definitive Additional Materials     ☐ Soliciting Material Pursuant to Section 240.14a-12 Agilent Technologies, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):               ☒ No fee required.     ☐ Fee paid previously with preliminary materials.     ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.         AGILENT TECHNOLOGIES, INC. 5301 Stevens Creek Blvd. Santa Clara, California 95051 (800) 227-9770 SUPPLEMENT TO THE PROXY STATEMENT FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MARCH 13, 2025   The following information supplements and amends the definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on January 31, 2025 (as amended or supplemented, the “Proxy Statement”) of Agilent Technologies, Inc. (the “Company”) and furnished to stockholders of the Company in connection with the solicitation of proxies by the board of directors of the Company for the 2025 annual meeting of stockholders to be held on March 13, 2025, and any adjournment or postponement thereof.   The Company is filing this Supplement solely to update the biography of Mikael Dolsten, M.D., Ph.D., as contained under the heading “Director Nominees for Election to New Three-Year Terms That Will Expire in 2028”, with respect to Proposal 1 (Election of Directors). The updated biography, as set forth below, reflects that Dr. Dolsten has an additional public company directorship that was not included in the Proxy Statement filed by the Company with the SEC on January 31, 2025 and furnished to stockholders of the Company.   The table and text below replace, in their entirety, the table headed “Mikael Dolsten, M.D., Ph.D.”, and the first paragraph on page 9 of the Proxy Statement:   MIKAEL DOLSTEN, M.D., Ph.D. Age: 66 Board Committees: Other Public Directorships: Director Since: September 2021 · Audit and Finance · Vimian Group &mid